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Abstract The cytosolic enzymes asymmetrical diadenosine
tetraphosphate hydrolase (EC 3.6.1.17, Ap4Aase) and diadeno-
sine triphosphate hydrolase (EC 3.6.1.29, Ap3Aase) are inhibited
competitively by suramin. Ap4Aase and Ap3Aase were assayed
in cytosolic rat brain extracts using fluorogenic analogues of the
respective substrates diadenosine tetraphosphate (Ap4A) and
diadenosine triphosphate (Ap3A). Ki values for suramin as
inhibitor of Ap4Aase and Ap3Aase were 5U1036 M and
3U1037 M, respectively. Results indicate that suramin or
suramin-like derivatives may be useful tools to investigate
diadenosine polyphosphate cleaving enzymes and that the
intracellular diadenosine polyphosphate metabolism may be a
pharmacological target of suramin with biological and clinical
implications.
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1. Introduction
Diadenosine polyphosphates (ApnA, n = 3^6) are a family
of dinucleotides with increasing biochemical and pharmaco-
logical signi¢cance as intra- and extracellular signalling mol-
ecules [1,2]. Some recent reports suggest that some ApnA are
involved in the intracellular regulation of ATP-gated K
channels [3,4], in the signalling mechanisms associated with
interferon actions [5] and in the mechanisms of di¡erentiation
and apoptosis in human cells [6]. These all contribute to an
increasing interest in ApnA. Speci¢c hydrolytic enzymes reg-
ulate the intracellular levels of these dinucleotides in mamma-
lian cells : asymmetrical Ap4Aase, a 20-kDa peptide, preferen-
tially cleaves Ap4A over Ap5A and Ap6A but not Ap3A or
Ap2A, and Ap3Aase, a 30-kDa peptide, hydrolyzes Ap3A but
not Ap4A or Ap2A [7,8]. It has recently been demonstrated
that the protein encoded by the putative human tumor sup-
pressor FHIT gene [9,10] displays enzymatic properties similar
to those of the previously characterized Ap3Aase.
Suramin is a symmetrical hexasulfonated naphthylamine
derivative of urea used therapeutically as antiparasitic, anti-
viral and anticancer drug but is severely limited by toxic side
e¡ects [11,12]. Suramin is also used in the pharmacology of
purinergic transmission since its e¡ects as antagonist of P2
purinoceptors and inhibitor of ecto-ATPases [13] and neural
ecto-ApnAase [14] have been reported. We now report inhib-
ition of the speci¢c Ap4A and Ap3A hydrolases present in rat
brain cytosol by suramin, using £uorogenic derivatives of
ApnA as substrates [15,16], and show that Ap3Aase is a par-
ticularly sensitive enzyme.
2. Materials and methods
Young Wistar male rats were killed by decapitation, brains rapidly
removed and homogenized in ice-cold 50 mM Tris-HCl pH 7.4 and
centrifuged at 100 000Ug for 1 h. Supernatants were dialyzed against
homogenization bu¡er and used as Ap4Aase and Ap3Aase source.
The £uorogenic substrates O-(ApnA), n = 2^5, were used to measure
enzymatic activities by continuous £uorimetric and chromatographic
assays [8,14]. Continuous assays were performed in £uorimeter micro-
cuvettes, containing Tris-HCl 50 mM, pH 7.5, 4 mM MgCl2 and
appropriate protein, substrate and inhibitor concentrations (250 Wl
¢nal volume) under stirring at 37‡C. A Hitachi F-2000 spectro£uorim-
eter (Vex 305 nm, Vem 410 nm) was used to record the £uorescence
increase associated with substrate hydrolysis. When necessary, results
of reaction rates were corrected for the quenching e¡ect of suramin on
the £uorescence emission of etheno compounds; quenching was noted
at suramin concentrations higher than 5 WM. HPLC analysis was
performed in a Waters instrument with a 470 £uorescence detector
(Vex 305 nm, Vem 410 nm). A Nova-Pak C18 column (Waters) was
eluted with 10 mM KPO4H2, 25% acetonitrile, 2 mM tetrabutylam-
monium bromide (Sigma), pH 7.0 at 0.8 ml/min. Preparation of O-
(ApnA) was as previously described [8]. Acetonitrile and salts used for
chromatographic analysis were HPLC grade from Merck and Schar-
lau. C. durissus phosphodiesterase was from Boehringer. Suramin was
from RBI. All other products were reagent grade.
3. Results
3.1. Hydrolysis of O-(ApnA) by rat brain extracts
The £uorogenic dinucleotides O-(Ap4A), O-(Ap5A) and O-
(Ap3A) but not O-(Ap2A) were hydrolyzed by rat brain cyto-
solic extracts. Using both continuous £uorimetric and chro-
matographic assays it was found that hydrolytic activity on O-
(Ap4A) and O-(Ap5A) was inhibited by Ap4, F3, Zn2 and
Ca2 ; however, O-(Ap3A) hydrolysis was not a¡ected by Ap4,
F3, Zn2 and Ca2 but by Zn2 (Fig. 1A,B). The lack of O-
(Ap2A) cleavage indicates the absence of non-speci¢c phos-
phodiesterase activity able to hydrolyze ApnA, n = 2^6 from
brain cytosol according to known results [17]. These results
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indicate that only the speci¢c hydrolases asymmetrical
Ap4Aase and Ap3Aase contributed to the cleavage of O-
(Ap4A) and O-(Ap3A), respectively. The O-nucleotide moieties
released from O-(Ap4A) and O-(Ap3A) by asymmetrical
Ap4Aase and Ap3Aase, O-ATP+O-AMP and O-ADP+O-AMP,
respectively, were catabolized by nucleotidases and/or phos-
phatases up to O-adenosine as the ¢nal product (Fig. 2A,B).
Km and speci¢c activity values obtained for Ap4Aase and
Ap3Aase were respectively: 2.1 þ 0.4 and 11.2 þ 1.7 WM, and
10.5 þ 1.8 and 2.3 þ 0.6 nmol/min/mg (n = 4).
3.2. Inhibition of asymmetrical Ap4Aase and Ap3Aase by
suramin
Addition of suramin (0.1^30 WM) to the reaction mixtures
in the £uorimeter cuvette produced immediate and sustained
decreases of the slope of £uorescence traces associated with
substrate hydrolysis. The slope changes induced by suramin
were dose dependent and were not modi¢ed after preincuba-
tion of suramin in the reaction mixture. HPLC assays clearly
demonstrated that the depressor e¡ect of suramin on £uores-
cence trace slopes was associated with a decrease in the sub-
strate cleavage e⁄ciency (Fig. 2C,D).
Fig. 3 shows comparatively the e¡ects of suramin on
Ap4Aase and Ap3Aase. Ap3Aase was found to be the most
sensitive enzyme showing a complete inhibition at suramin
concentrations higher than 6 WM. Increased substrate concen-
tration in the reaction mixture attenuated suramin inhibition,
suggesting competition between substrate and inhibitor at the
binding site. Double reciprocal plots obtained for Ap4Aase
and Ap3Aase were compatible with a competitive inhibition
pattern by suramin (Fig. 4). Ki values determined from these
plots were 5.03 þ 0.91 WM and 0.31 þ 0.04 WM for Ap4Aase
and Ap3Aase, respectively, with Km/Ki quotients of 0.4 and
36. A Km/Ki quotient of 36 indicates that Ap3Aase exhibits
much greater a⁄nity for suramin than for its own substrate
Ap3A, although this is not the case for Ap4Aase.
4. Discussion
Rat brain cytosolic activities hydrolyzing the £uorogenic
substrates of Ap4A and Ap3A display the typical character-
istics of asymmetrical Ap4Aase and Ap3Aase from bovine
adrenomedullary tissue and various other mammalian sources
[7,8]. Both Km and speci¢c activities determined for these
speci¢c hydrolases compare well with those determined for
enzymes from various rat organs, including the brain using
Ap4A and Ap3A as substrates [8].
These Ki values for suramin as inhibitor of speci¢c
ApnAases are within the range of lower Ki values reported
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Fig. 1. E¡ect of several typical inhibitors of Ap4Aase and Ap3Aase
on the hydrolysis of (A) O-(Ap4A) and (B) O-(Ap3A) by rat brain cy-
tosolic extracts. Linear £uorescence increases were recorded from re-
action mixtures for at least 5 min to determine control slopes (1)
and slopes in the presence of: (2) Ca2 1 mM; (3) Ca2 6 mM; (4)
F3 200 WM; (5) Ap4 10 WM; (6) Zn2 150 WM. Activities are ex-
pressed as percentages (means, n = 3) of slope in the presence of in-
hibitor relative to control slope. Hydrolysis of O-(Ap5A) showed a
closely similar inhibitory pro¢le to that of O-(Ap4A) and hydrolysis
of O-(Ap2A) was not detectable (not shown).
Fig. 2. Chromatographic pro¢les demonstrating the hydrolysis of O-
(Ap3A) by rat brain cytosolic extracts and the inhibitory e¡ect of
suramin on the dinucleotide hydrolysis. 5-Wl aliquots from reaction
mixtures of 100 Wl containing 10 WM O-(Ap3A) and incubated at
37‡C were taken at 0 and 20 min and injected into the chromato-
graph. A: Control, 0 min. B: Hydrolysis control without suramin,
20 min. C: Hydrolysis in the presence of 2 WM suramin, 20 min.
D: Hydrolysis in the presence of 6 WM suramin, 20 min. Inhibition
of O-(Ap4A) hydrolysis by suramin was also demonstrated by similar
experiments (not shown).
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for most suramin-sensitive enzymes [11,14,18,19]. Competitive
inhibition for Ap4Aase and Ap3Aase suggests that suramin, a
polyanionic molecule, interacts primarily by electrostatic in-
teractions with positively charged amino acid residues in-
volved in the binding of the negatively charged substrates
Ap4A and Ap3A. Hydrophobic interactions due to suramin
polyaromatic rings and hydrogen bonding probably also con-
tribute to suramin binding. Other enzymes using nucleotide
substrates, e.g. ATP, like human folylpolyglutamate synthe-
tase [18] or a Xenopus oocyte ecto-ATPase [20] have been
reported to be competitively inhibited by suramin. We have
tentatively proposed that lysine is not involved in substrate
binding in bovine adrenomedullary Ap4Aase [8]; consequently
histidine and/or arginine could be involved in the binding of
Ap4A to Ap4Aase. The complete inactivation of both asym-
metrical Ap4Aase and Ap3Aase observed after preincubation
of brain extracts with diethyl pyrocarbonate (unpublished ob-
servations) strongly suggests the presence of catalytically ac-
tive histidine residues in both enzymes.
The similarity between the catalytic properties of FHIT
protein [9] and Ap3Aase (EC 3.6.1.29), an enzyme known
for years [7], suggests that both could be the same protein.
If this is so, it may then be predicted that suramin will be a
FHIT protein-binding drug inhibiting its associated Ap3Aase
activity, which opens the question of the biological activity
displayed by putative FHIT-suramin complexes.
Inhibition of Ap4Aase and Ap3Aase by suramin may have
clinical and biological relevance. When used therapeutically,
suramin serum concentrations in treated patients may be high-
er than 200 WM with a measured half-life of about 50 days
and it has been reported that the drug may inhibit in vivo
cytosolic, lysosomal, and nuclear enzymes [11,12,21,22]. Thus,
suramin inhibition of ApnA hydrolases is a feasible event that
could contribute partly to the great diversity of toxic e¡ects
described for suramin by increasing cellular ApnA levels.
Raised intracellular ApnA levels caused by suramin inhib-
ition of both ApnA hydrolases could interfere with cellular
energy metabolism through the very strong inhibition of ad-
enosine and adenylate kinases by Ap4A and Ap5A [23,24] or
with the normal regulation of ATP-gated K channels, which
are also ApnA-binding proteins [3,4]. It is worth noting that
increased Ap3A levels have recently been correlated with cel-
lular di¡erentiation in responsive human cells treated by in-
terferons [5,6] and that suramin can induce cell di¡erentiation
[25]. This raises the question whether suramin induced di¡er-
entiation could be mediated by increased Ap3A levels or
changes in the Ap3A/Ap4A ratio, a recently proposed sensitive
indicator of cell status [6].
This study adds asymmetrical Ap4Aase and Ap3Aase to the
list of enzymes inhibited by suramin. Since there are no suit-
able inhibitors of these enzymes, our results suggest that sur-
amin or suramin-derived compounds more speci¢cally inhib-
iting these ApnA hydrolases could be tools to further
investigate molecular aspects of ApnA-cleaving enzymes in-
cluding FHIT protein, and also the intracellular roles of
ApnA, still a puzzling question far from being clearly under-
stood.
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